Ensign Group, Inc ENSG
Deals with insiders in the proxy filed Apr 2, 2026
Proxy, Item 404Deals between ENSG and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 4, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 4, 2025.
Family Relationships“Julie Uychiat is the sister of our board member, Marivic Uychiat Pison. Ms. Julie Uychiat has served as a Clinical Resource to one of our independent operating subsidiaries since April 2002. As a Clinical Resource, Ms. Julie Uychiat's responsibilities include providing clinical and leadership support to the independent operating subsidiaries. These support services include regulatory guidance, recruitment and development of clinical leaders and accountability for overall clinical results. From January 1, 2025 through December 31, 2025, Ms. Julie Uychiat earned a total compensation of $157,850. Total cash compensation included a bonus of $30,000, that was earned in 2025. In addition, we granted Ms. Julie Uychiat 500 stock options on May 15, 2025.”
Read it in the proxyopen_in_new
The whole section
As filed
11 paragraphs quoted as filed
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS“Since January 1, 2025, there has not been, nor is there any proposed transaction in which we were or will be a party, involving an amount that exceeded or will exceed $120,000 and in which any director, executive officer, beneficial owner of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the compensation arrangements and other agreements and transactions which are described in "Executive Compensation" section and the transactions described below.”
Read it in the proxyopen_in_new
Family Relationships“Clayton Christensen is the brother of our co-founder, Christopher R. Christensen, who retired as a member of the Board on September 1, 2025. Mr. Clayton Christensen has served as our Chief Human Capital Officer since September 2016. As Chief Human Capital Officer, Mr. Clayton Christensen is responsible for our recruiting and retention programs as well as our training and professional growth program, a key element of our talent-driven management approach. From January 1, 2025 through December 31, 2025, Mr. Clayton Christensen earned a total cash compensation of $1,460,552. Total compensation included a bonus of $1,150,000, which was earned in 2025. On November 5, 2025, we granted Mr. Clayton Christensen 1,200 restricted stock awards with a fair value of $189.93 per share, that vests over a five-year period from the grant date for aggregate stock compensation of $227,916. Additionally, we granted him 3,000 stock options on November 5, 2025.”
Read it in the proxyopen_in_new
Family Relationships“Corwin Lewis is the brother-in-law of our Chief Operating Officer, Spencer W. Burton. Mr. Corwin Lewis has served as our Market Leader of Emerald Healthcare, Inc., Ensign Services’ Midwest-based portfolio company since June 2021. As Market Leader, Mr. Corwin Lewis's responsibilities include providing leadership to the local executive directors, clinical, managerial and custodial teams. From January 1, 2025 through December 31, 2025, Mr. Corwin Lewis earned a total compensation of $1,051,122. Total cash compensation included a bonus of $847,991, which was earned in 2025. On August 21, 2025, we granted Mr. Corwin Lewis 800 restricted stock awards with a fair value of $169.24 per share that vests over a five-year period from the grant date for aggregate stock compensation of $135,392. Additionally, we granted him 2,000 stock options on August 21, 2025.”
Read it in the proxyopen_in_new
Family Relationships“Ryan Ross is the brother-in-law of our Chief Investment Officer, Chad A. Keetch. Mr. Ryan Ross has served as the Executive Director to one of our independent operating subsidiaries since April 2021. As Executive Director, Mr. Ryan Ross is responsible for managing the operations of the independent operating subsidiary in order to provide excellent patient care. His responsibilities include coordinating and providing leadership to the clinical, managerial and custodial teams. From January 1, 2025 through December 31, 2025, Mr. Ryan Ross earned a total compensation of $285,173. Total cash compensation included a bonus of $131,683, which was earned in 2025. On November 5, 2025, we granted Mr. Ryan Ross 600 restricted stock awards with a fair value of $189.93 per share that vests over a five-year period from the grant date for aggregate stock compensation of $113,958. Additionally, we granted him 1,500 stock options on November 5, 2025.”
Read it in the proxyopen_in_new
Family Relationships“Julie Uychiat is the sister of our board member, Marivic Uychiat Pison. Ms. Julie Uychiat has served as a Clinical Resource to one of our independent operating subsidiaries since April 2002. As a Clinical Resource, Ms. Julie Uychiat's responsibilities include providing clinical and leadership support to the independent operating subsidiaries. These support services include regulatory guidance, recruitment and development of clinical leaders and accountability for overall clinical results. From January 1, 2025 through December 31, 2025, Ms. Julie Uychiat earned a total compensation of $157,850. Total cash compensation included a bonus of $30,000, that was earned in 2025. In addition, we granted Ms. Julie Uychiat 500 stock options on May 15, 2025.”
Read it in the proxyopen_in_new
Indemnification Provisions“We have entered into indemnification agreements with each of our directors, officers and certain key employees. These indemnification agreements, along with our Certificate of Incorporation and Bylaws, require us to indemnify such persons to the fullest extent permitted by Delaware law.”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“Our Audit Committee does and will continue to review potential conflict of interest situations and any future proposed transaction, or series of transactions, with related persons on an ongoing basis, and either approve or disapprove each reviewed transaction or series of related transactions with related persons. On August 14, 2007, we adopted a written policy and set of procedures with respect to related person transactions (the "Related Person Transaction Policy"), which includes specific provisions for the approval of related person transactions. Pursuant to the Related Person Transaction Policy, a "related person transaction" is defined as a transaction, arrangement or relationship or series of similar transactions, arrangements or relationships, in which we and certain enumerated related persons participate, the amount involved exceeds $120,000 and the related person has a direct or indirect material interest therein. Related person transactions include any existing or currently proposed transaction or series of similar transactions for which disclosure under Item 404(a) of SEC Regulation S-K is mandated. The term “related person” under SEC rules means, at the applicable time, (a) any director or executive officer of the Company, (b) any nominee to the Board of Directors, (c) any beneficial owner of more than 5% of Ensign stock, and (d) any immediate family member (as defined by SEC rules) of any of those directors, executive officers, nominees, or beneficial owners. An indirect material interest can arise from a related person’s position or relationship with a firm, corporation, or other entity that engages in a transaction with the Company).”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“In the event that a related person transaction is identified, such transaction must be reviewed and approved or ratified by our Audit Committee. If it is impracticable for our Audit Committee to review such transaction, pursuant to the policy, the transaction will be reviewed by the Chair of our Audit Committee, whereupon the Chair of our Audit Committee will report to the Audit Committee the approval or disapproval of such transaction.”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“In reviewing and approving related person transactions, pursuant to the Related Person Transaction Policy, the Audit Committee, or its Chair, considers all information that the Audit Committee, or its Chair, believes to be relevant and important to a review of the transaction and approves only those related person transactions that are determined to be in, or not inconsistent with, our best interests and that of our stockholders, taking into account all available relevant facts and circumstances available to the Audit Committee or its Chair. Pursuant to the Related Person Transaction Policy, these facts and circumstances will typically include, but not be limited to, the benefits of the transaction to us; the impact on a director's independence in the event the related person is a director, an immediate family member of a director or an entity in which a director is a partner, stockholder or executive officer; the availability of other sources for comparable products or services; the terms of the transaction; and the terms of comparable transactions that would be available to unrelated third parties or to employees generally. Pursuant to the Related Person Transaction Policy, no member of the Audit Committee shall participate in any review, consideration or approval of any related person transaction with respect to which the member or any of his or her immediate family members is the related person.”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“In accordance with the Related Person Transaction Policy, the Audit Committee has reviewed and approved the compensation payable to Clayton Christensen, Ryan Ross, Corwin Lewis and Julie Uychiat. For additional information see “Certain Relationships and Related Party Transactions - Family Relationships” above.”
Read it in the proxyopen_in_new
Policies and Procedures for Transactions with Related Persons“There has been no transaction since January 1, 2025 that is required to be reported under Item 404(a) but that did not require review and approval or ratification under the Related Person Transaction Policy or for which the Related Person Transaction Policy was not followed.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENSG/export.csv") into a cell.